Skip to main content
SpringerLink
Log in

Complications of androgen-deprivation therapy in men with prostate cancer

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Androgen-deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reducing them. It is important for clinicians to anticipate these effects and to initiate measures to prevent or minimize them in order to maintain quality of life in prostate cancer survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Caubet JF, Tosteson TD, Dong EW, et al.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49:71 -78.

    Article  PubMed  CAS  Google Scholar 

  2. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002, 360:103 -108.

    Article  PubMed  CAS  Google Scholar 

  3. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781–1788.

    Article  PubMed  CAS  Google Scholar 

  4. Herr HW, O’Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000, 163:1743 -1746.

    Article  PubMed  CAS  Google Scholar 

  5. Potosky AL, Knopf K, Clegg LX, et al.: Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001, 19:3750 -3757.

    PubMed  CAS  Google Scholar 

  6. Fowler FJ, Collins MM, Corkery EW, et al.: The impact of androgen deprivation on quality of life after radical prostatectomy for prostate adenocarcinoma. Cancer 2002, 95:287 -295.

    Article  PubMed  Google Scholar 

  7. Potosky AL, Reeve BB, Clegg LX, et al.: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002, 94:430 -437. This substudy within the Prostate Cancer Outcomes Study assessed quality of life in a random sample of 661 men with clinically localized prostate cancer who were either observed or treated with androgen deprivation. Although men receiving androgen deprivation therapy reported more sexual dysfunction, physical discomfort, and fatigue, they were more likely to be satisfied with their treatment decision than men on no therapy.

    PubMed  Google Scholar 

  8. Iversen P, Tyrrell CJ, Kaisary AV, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000, 164:1579 -1582.

    Article  PubMed  CAS  Google Scholar 

  9. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P: Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1998, 1:289 -296.

    Article  PubMed  CAS  Google Scholar 

  10. Kouriefs C, Georgiou M, Ravi R: Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int 2002, 89:379 -383.

    Article  PubMed  CAS  Google Scholar 

  11. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB: Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000, 55:97 -101.

    Article  PubMed  CAS  Google Scholar 

  12. Loprinzi CL, Michalak JC, Quella SK, et al.: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331:347 -352.

    Article  PubMed  CAS  Google Scholar 

  13. Sartor O, Eastham JA: Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 1999, 92:415 -416.

    PubMed  CAS  Google Scholar 

  14. Loprinzi CL, Goldberg RM, O’Fallon JR, et al.: Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol 1994, 151:634 -636.

    PubMed  CAS  Google Scholar 

  15. Quella SK, Loprinzi CL, Sloan J, et al.: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999, 162:98 -102.

    Article  PubMed  CAS  Google Scholar 

  16. Roth AJ, Scher HI: Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 1998, 7:129 -132.

    Article  PubMed  CAS  Google Scholar 

  17. Hammar M, Frisk J, Grimas O, et al.: Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999, 161:853 -856.

    Article  PubMed  CAS  Google Scholar 

  18. Spetz AC, Hammar M, Lindberg B, et al.: Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001, 166:517 -520.

    Article  PubMed  CAS  Google Scholar 

  19. McLeod DG, Iversen P: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000, 56:713 -720.

    Article  PubMed  CAS  Google Scholar 

  20. Staiman VR, Lowe FC: Tamoxifen for flutamide/finasterideinduced gynecomastia. Urology 1997, 50:929 -933.

    Article  PubMed  CAS  Google Scholar 

  21. Smith MR, Kaufman D, George D, et al.: Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 2002, 95:1864 -1868.

    Article  PubMed  CAS  Google Scholar 

  22. Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599 -603.

    Article  PubMed  CAS  Google Scholar 

  23. Xu X, De Pergola G, Bjorntorp P: The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990, 126:1229 -1234.

    Article  PubMed  CAS  Google Scholar 

  24. Nowicki M, Bryc W, Kokot F: Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Invest 2001, 24:31 -36.

    PubMed  CAS  Google Scholar 

  25. Smith JC, Bennett S, Evancs LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261–4267. This clinical study assessed changes in body composition, serum insulin and lipids, and radial artery stiffness in 22 men with prostate cancer treated with 3 to 6 months of androgen deprivation therapy. It is one of the few reported studies documenting cardiovascular changes associated with androgen deprivation.

    Article  PubMed  CAS  Google Scholar 

  26. Segal RJ, Reid RD, Courneya KS, et al.: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21:1653 -1659.

    Article  PubMed  Google Scholar 

  27. Daniell HW, Dunn SR, Ferguson DW, et al.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181 -186.

    Article  PubMed  CAS  Google Scholar 

  28. Melton LJ, Alothman KI, Khosla S, et al.: Fracture risk following bilateral orchiectomy. J Urol 2003, 169:1747 -1750.

    Article  PubMed  Google Scholar 

  29. Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of the adult skeleton. Endocrine Rev 2002, 23:279 -302. This comprehensive review discusses the physiologic effects of estrogen and androgens on bone metabolism and their relative roles in age-related bone loss in men and women.

    Article  CAS  Google Scholar 

  30. Taxel P, Fall PM, Albertsen PC, et al.: The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:4907 -4913.

    Article  PubMed  CAS  Google Scholar 

  31. Eriksson S, Eriksson A, Stege R, et al.: Bone mineral density in patients with prostate cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995, 57:97 -99.

    Article  PubMed  CAS  Google Scholar 

  32. Tyrrell CJ, Blake GM, Iversen P, et al.: The non-steroidal antiandrogen, bicalutamide (’Casodex’), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol 2003, 21:37 -42.

    PubMed  CAS  Google Scholar 

  33. Santini D, Gentilucci UV, Vincenzi B, et al.: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003, 14:1468 -1476. This review discusses the mechanisms of action of bisphosphonates on osteoclasts as well as their direct antitumor effects, including effects on growth factor release in the bone microenvironment, effects on cancer cell adhesion and invasion, proapoptotic effects on cancer cells, and antiangiogenic effects.

    Article  PubMed  CAS  Google Scholar 

  34. Saad F, Gleason DM, Murray R, et al.: A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458 -1468.

    PubMed  CAS  Google Scholar 

  35. Diamond TH, Winters J, Smith A, et al.: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444 -1450.

    Article  PubMed  CAS  Google Scholar 

  36. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948 -955.

    Article  PubMed  CAS  Google Scholar 

  37. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.

    Article  PubMed  CAS  Google Scholar 

  38. Smith MR: Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003, 97(Suppl):789 -795.

    Article  PubMed  Google Scholar 

  39. Besa EC: Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Semin Hematol 1994, 31:134 -145.

    PubMed  CAS  Google Scholar 

  40. Strum SB, McDermed JE, Scholz MC, et al.: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933 -941.

    PubMed  CAS  Google Scholar 

  41. D’Amico AV, Saegaert T, Chen MH, et al.: Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 2002, 95:275 -280.

    Article  PubMed  Google Scholar 

  42. Vollmer RT, Kantoff PW, Dawson NA, et al.: Importance of serum hemoglobin in hormone refractory prostate cancer. Clin Cancer Res 2002, 8:1049 -1053.

    PubMed  Google Scholar 

  43. Littlewood TJ, Bajetta E, Nortier JWR, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865 -2874.

    PubMed  CAS  Google Scholar 

  44. Quirt I, Robeson C, Lau CY, et al.: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001, 19:4126 -4134.

    PubMed  CAS  Google Scholar 

  45. Johansson JE, Wersall P, Brandberg Y, et al.: Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer: a randomized study. Scand J Urol Nephrol 2001, 35:288 -294.

    Article  PubMed  CAS  Google Scholar 

  46. Nakamura N, Fujita H, Kawata M: Effects of gonadectomy on immunoreactivity for choline acetyltransferase in the cortex, hippocampus, and basal forebrain of adult male rats. Neuroscience 2002, 109:473 -485.

    Article  PubMed  CAS  Google Scholar 

  47. Kritzer MF, Adler A, Marotta J, et al.: Regionally selective effects of gonadectomy on cortical catecholamine innervation in adult male rats are most disruptive to afferents in prefrontal cortex. Cereb Cortex 1999, 9:507–518.

    Article  PubMed  CAS  Google Scholar 

  48. Hammond J, Le Q, Goodyer C, et al.: Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 2001, 77:1319 -1326.

    Article  PubMed  CAS  Google Scholar 

  49. Pirl WF, Siegel GI, Goode MJ, Smith MR: Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 2002, 11:518 -523.

    Article  PubMed  Google Scholar 

  50. Barrett-Connor E, Goodman-Gruen D, Patay B: Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999, 84:3681 -3685.

    Article  PubMed  CAS  Google Scholar 

  51. Janowsky JS, Oviatt SK, Orwoll ES: Testosterone influences spatial cognition in older hypogonadal men. Behav Neuroscience 1994, 108:325 -332.

    Article  CAS  Google Scholar 

  52. Janowsky JS, Chavez B: Sex steroids modify working memory. J Cognitive Neuroscience 2000, 12:407 -414.

    Article  CAS  Google Scholar 

  53. Cherrier MM, Anawalt BD, Herbst KL, et al.: Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. J Clin Endocrinol Metab 2002, 87:3090 -3096.

    Article  PubMed  CAS  Google Scholar 

  54. HJ, Pakenham KI, Headley BC, et al.: Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002, 90:427–432. This is the first published study documenting cognitive dysfunction resulting from androgen deprivation in men in the setting of a randomized trial.

    Article  Google Scholar 

  55. Salminen E, Portin R, Korpela J, et al.: Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003, 89:971 -976.

    Article  PubMed  CAS  Google Scholar 

  56. Stone P, Hardy J, Huddart R, et al.: Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000, 36:1134 -1141.

    Article  PubMed  CAS  Google Scholar 

  57. Moinpour CM, Savage MJ, Troxel A, et al.: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998, 90:1537 -1544.

    Article  PubMed  CAS  Google Scholar 

  58. Burnham TR, Wilcox A: Effects of exercise on physiological and psychological variables in cancer survivors. Med Sci Sports Exerc 2002, 34:1863 -1867.

    Article  PubMed  Google Scholar 

  59. Sarhill N, Walsh D, Nelson KA, et al.: Methylphenidate for fatigue in advanced cancer patients: a prospective open-label study. Am J Hosp Palliat Care 2001, 18:187 -192.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, College of Physicians and Surgeons, Columbia University, 177 Fort Washington Avenue, MHB 6-435, 10032, New York, NY, USA

    Allen C. Chen MD & Daniel P. Petrylak MD

Authors
  1. Allen C. Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel P. Petrylak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, A.C., Petrylak, D.P. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep 6, 210–216 (2005). https://doi.org/10.1007/s11934-005-0009-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0009-2

Keywords

Search

Navigation